Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Evan J. Lipson, MD, Johns Hopkins Medicine
Advertisement
Articles by Evan J. Lipson, MD, Johns Hopkins Medicine
Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.
Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.
Advertisement
Latest Updated Articles
Dr. Lipson on the Role of ctDNA Testing in MelanomaDecember 8th 2021
Balancing Safety and Efficacy in Adjuvant TherapyDecember 14th 2020
Adjuvant Clinical Trial Data Impact on Treatment SelectionDecember 14th 2020
Metastatic Melanoma Long-Term Survival DataDecember 14th 2020
Short-Term COVID-19 NCCN RecommendationsDecember 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5